Flex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 >Results of Operations and Financial Condition.
announcing its financial results for the quarter ended March 31,
2017. A copy of the press release is attached hereto as Exhibit
99.1 and incorporated herein by reference.
being furnished and shall not be deemed filed for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
the Exchange Act, or otherwise subject to the liabilities of that
section, nor shall they be deemed incorporated by reference into
any filing under the Exchange Act or the Securities Act of 1933,
as amended, except as expressly set forth by specific reference
in such filing.
|
Exhibit No.
|
Description
|
||
|
99.1
|
Press Release of Flex Pharma, Inc. dated May 3, 2017.
|
||
About Flex Pharma, Inc. (NASDAQ:FLKS)
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs. Flex Pharma, Inc. (NASDAQ:FLKS) Recent Trading Information
Flex Pharma, Inc. (NASDAQ:FLKS) closed its last trading session down -0.01 at 3.36 with 47,092 shares trading hands.